During the past decade, Negroski, Sutherland and Hanes Neurology conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Negroski, Sutherland and Hanes Neurology" #1 collaborator was "Bayer" with 2 trials as a collaborator and "Mallinckrodt ARD Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Negroski, Sutherland and Hanes Neurology" are "Multiple Sclerosis, Relapsing-Remitting" (3 trials) and "Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Negroski, Sutherland and Hanes Neurology" in a lesser frequency.

Most popular intervention types in "Negroski, Sutherland and Hanes Neurology" are "Biological" (2 trials), "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Alemtuzumab 12 mg" (1 trials), "Alemtuzumab 24 mg" (1 trials), "Dalfampridine-ER 10mg" (1 trials), "Dalfampridine-ER 5mg" (1 trials) and "Interferon beta-1a" (1 trials). Other intervention names were less common.

The vast majority of trials in "Negroski, Sutherland and Hanes Neurology" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Negroski, Sutherland and Hanes Neurology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Negroski, Sutherland and Hanes Neurology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Negroski, Sutherland and Hanes Neurology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".